;

Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer

13/09/2019

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that Stewart Kay has been appointed as the Companys Chief Business Officer (CBO).

Stewart joins Crescendo following over 20 yearsexperience in business development in both biotech and big pharma. Most recently he was Senior Director, Transactions, at GlaxoSmithKline (GSK), in the Worldwide Business Development group. During his time at GSK, Stewart was the lead negotiator on a wide variety of deals across multiple therapeutic areas including oncology, immuno-inflammation, respiratory and rare diseases. He was responsible for a range of early and late stage clinical in- and out- licensing agreements and numerous transactions relating to pre-clinical assets and technology platforms.

Before joining GSK, Stewart also held senior roles in business development and marketing at Asterand plc, Evotec AG and Amersham Biosciences (now GE Healthcare). He holds a BSc (Hons) in Biochemistry, and an MBA from Warwick University Business School.

Theodora Harold, CEO of Crescendo Biologics, said: Stewart has an impressive track record of leading negotiations across a broad range of transactions in the biotech and pharmaceutical sectors. With our lead programme for PSMA positive tumours entering phase I soon, and a number of innovative, first-in-class, T cell enhancing programmes following behind, 2020 will be an important year for us. Stewarts extensive experience will be indispensable to us as we drive Crescendo forward.

Stewart Kay, CBO of Crescendo Biologics, commented: I am excited to join the Crescendo team. Crescendo has made great progress over the past few years and has established itself as a key player in the CD137 space with the acceleration of its lead programme, CB307, towards the clinic. I am impressed by the progress made in the collaboration with Takeda and am looking forward to working with the rest of the team to realise the potential of Humabody® therapeutics.

 

Article sourced from: https://www.crescendobiologics.com/wp-content/uploads/2019/09/190905-Crescendo-CBO-appointment-Press-Release.pdf
Published on: 05/09/2019

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;